A Phase 3 interventional study of Sonelokimab and Placebo in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Active, not recruiting at 182 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by MoonLake Immunotherapeutics AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Arthritis, Psoriatic with a site in Poland — 6 open to participants now, 25 under way, 18 of them phase 3. Arthritis, Psoriatic · Poland.
Among the 92 studies in Arthritis, Psoriatic with a site in Poland, this one is the 7th largest by planned enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2024, is one of 61 in phase 3, reaches primary completion later than 6 of the 24 other live ones, and was the 79th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →6 of the 92 studies in Arthritis, Psoriatic with a site in Poland are open now. Recruiting first, the newest first:
Takeda · Sites in Poland, United States, Argentina and 17 more countries
Ages 18+
UCB Biopharma SRL · Sites in Poland, United States, Bulgaria and 3 more countries
Ages 18+
AbbVie · Sites in Poland, United States, Canada and 3 more countries
Ages 18+
AbbVie · Sites in Poland, Argentina, Austria and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 15 more countries
Ages 3+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 23 · Phase 3 63 · Phase 4 5
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 960 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 399 across the 90 interventional studies, 1,005 across the 2 observational. Of the 66 that completed or were terminated, 54 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 92 have an industry lead sponsor. The 10 most frequent:
MoonLake Immunotherapeutics AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
MoonLake Immunotherapeutics AG has 4 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
9 of the studies in Arthritis, Psoriatic with a site in Poland that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 9 to your calendar (.ics) → With an account.
Among the 92 studies in Arthritis, Psoriatic with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
M1095-PSA-301 is a Phase 3, multicenter, randomized, parallel-group, double-blind, 3-arm, placebo-controlled study to investigate the efficacy and safety of sonelokimab 60 mg every 4 weeks (with and without an induction regimen) versus placebo in adults with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive sonelokimab subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dosing starting at Week 8.
Drug: Sonelokimab
Subjects randomized to this arm will receive sonelokimab subcutaneously every 4 weeks.
Drug: Sonelokimab
Subjects randomized to this arm will receive placebo subcutaneously.
Drug: Placebo
Randomized treatment, parallel-group
Randomized treatment, parallel-group
Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)
Proportion of participants achieving ACR50
Time frame: Week 16
Response rate of participants achieving at least 20% improvement in the American College of Rheumatology criteria (ACR20)
Proportion of participants achieving ACR20
Time frame: Week 16
Response rate of participants achieving Minimal Disease Activity (MDA)
Proportion of participants achieving MDA
Time frame: Week 16
Health Assessment Questionnaire- Disability Index (HAQ-DI)
Change in HAQ-DI from baseline
Time frame: Week 16
Psoriasis Area and Severity Index (PASI90)
Proportion of participants achieving a decrease of ≥90% in the PASI90 response at Week 16 in the subgroup of participants with psoriasis (PsO) involving ≥3% body surface area at baseline
Time frame: Week 16
Short- form-36 (SF-36) Physical Component Summary (PCS)
Change from Baseline in SF-36 PCS at Week 16
Time frame: Week 16
van der Heijde modified Total Sharp Score (vdHmTSS)
Change from Baseline to Week 16 in joint/bone structural damage (vdHmTSS)
Time frame: Week 16
Showing the first 100 of 182 sites across 20 countries. Choose a country and city above to see the rest.
Ran from Oct 2024 to primary completion in May 2026, 19 months.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → May 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
MoonLake Immunotherapeutics AG